Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Transplantation|January 14, 2020
Liposomal Delivery Improves the Efficacy of Prednisolone to Attenuate Renal Inflammation in a Mouse Model of Acute Renal Allograft RejectionCarla M A van Alem, Martina Schmidbauer, Song Rong, et al.
BMC Public Health|October 27, 2021
Burden of informal care in stroke survivors and its determinants: a prospective observational study in an Asian settingYi Wang, Shilpa Tyagi, Helen Hoenig, et al.
Ebiomedicine|June 25, 2023
Time-restricted feeding attenuates hypercholesterolaemia and atherosclerosis development during circadian disturbance in APOE∗3-Leiden.CETP miceWietse In Het Panhuis, Milena Schönke, Melanie Modder, et al.
The Journal of Prevention of Alzheimer'S Disease|March 13, 2025
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paperGursimar Bhalla, Pricilia Tanoto, Ashwati Vipin, et al.
Plos One|January 29, 2019
Health-related quality of life loss associated with first-time strokeYen Shing Yeoh, Gerald Choon-Huat Koh, Chuen Seng Tan, et al.
Journal of Medicinal Chemistry|January 7, 2005
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesDooseop Kim, Liping Wang, Maria Beconi, et al.
The Lancet. Oncology|February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trialJohann S de Bono, Nicole Concin, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 5, 2019
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical CancerDavid S Hong, Nicole Concin, Ignace Vergote, et al.
Diabetes|September 28, 2005
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9George R Lankas, Barbara Leiting, Ranabir Sinha Roy, et al.
Journal of Medicinal Chemistry|June 9, 2006
(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesScott D Edmondson, Anthony Mastracchio, Robert J Mathvink, et al.
Pageof 12